II. Indications
- Patient unable to take medication by oral or Parenteral Route
III. Contraindications
- Rectal lesions
- Significant Diarrhea
- Neutropenia
- Large stool burden or Fecal Impaction
- Timed release medications
- Enteric coated medications
- Medications known to cause Esophagitis (similar risk to rectal mucosa)
- Oral Antibiotics
- Altered Pharmacokinetics by rectal route
IV. Mechanism
- Many medications are well absorbed systemically by the rectal mucosa
- Distal rectal medications avoid first pass metabolism
- Distal middle and inferior Rectal Veins drain directly into the inferior vena cava
- Pitfalls
- Some medications have variable or erratic rectal absorption
- Altered bowel function may limit rectal use (profuse Diarrhea, stool impaction)
- Distal rectal mucosa has limited surface area for absorption
V. Medications: Locally Active Medications
VI. Medications: Systemically Active Medications
-
Analgesics
- Acetaminophen suppository
- Aspirin suppository
- Ibuprofen suppository
- Diclofenac suppository
- Indomethacin suppository
- Oxycodone Suppository
- Morphine Suppository
-
Antiemetics
- Ondansetron Suppository
- Prochlorperazine Suppository
- Promethazine Suppository
- Metoclopramide Suppository
-
Benzodiazepines (e.g. Status Epilepticus)
- Rectal Diazepam (gel, enema)
-
Migraine Medications
- Caffeine and Ergotamine Suppository
- Sumatriptan suppository
VII. Medications: Oral Formulations Given Rectally
- Some oral medications may be crushed and delivered rectally
- Do NOT give timed release medications rectally
- Do NOT give enteric coated medications rectally
- Do NOT give medications rectally that are known to cause Esophagitis
- Do NOT give oral Antibiotics rectally (altered Pharmacokinetics, exceptions may exist)
- Example medications
- Antiplatelet agents (Aspirin, Clopidogrel, Ticagrelor)
- Consult pharmacist on oral medications that may be given by rectal route
- Rectal administration
- Crush oral tablet and mix with 10-20 ml water
- Instill solution into Rectum via angiocatheter or commercial device
VIII. References
- Swaminathan and Fisher (2025) EM:Rap, 7/21/2025
- Hua (2019) Front Pharmacol 10:1196 +PMID: 31680970 [PubMed]